Experimental eczema drug trial halted before results

NCT ID NCT06119529

Terminated Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study aimed to test the safety of a new drug called LY3872386 in healthy volunteers and people with atopic dermatitis (eczema). The trial was terminated early, so no meaningful data on safety or how the body processes the drug were collected. Only 18 participants were planned, making this a very preliminary investigation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3872386
What could go wrong: This was a very early, small study that was terminated, so no results are available. It is unclear if the drug is safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS HEALTHY

Contacts and locations

Locations

CenExel ACT

Anaheim, California, 92801, United States
Fortrea Clinical Research Unit

Daytona Beach, Florida, 32117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.